Sun Pharma ends deal to take over Israeli unit Taro

Fri Feb 8, 2013 9:50pm IST

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries Ltd (SUN.NS), which has been on a buying spree, ended its agreement to gain full control over its Israeli unit Taro Pharmaceutical Industries Ltd (TARO.N).

The companies decided that ending the deal was in the best interest of their shareholders, Sun Pharma and Taro said in a statement.

"The decision (to not merge Taro) could prove beneficial for Sun Pharma as long as Taro is generating good cash flow," said Siddhant Khandekar, an analyst at ICICI Direct in Mumbai.

"There might be structural issues while handling Taro, but it won't hurt Sun to a large extent."

Sun Pharma had last offered $39.50 per share, or about $571 million, for the one-third stake it did not already own in Taro, seemingly winning over the Israeli company's board following a long battle to gain full control of the U.S.-listed drugmaker.

Raising the price beyond $39.50 per share did not make any sense for Sun Pharma, Khandekar said.

Sun Pharma, India's biggest drugmaker by market value, remains one of the few Indian pharma companies that has done successful international acquisitions at a time when global pharmaceutical giants such as Abbott Laboratories (ABT.N) and Sanofi SA (SASY.PA) have been buying out Indian drug companies at high valuations.

Sun Pharma bought U.S.-based Dusa Pharmaceuticals Inc DUSA.O for about $230 million and URL Pharma from Japan's Takeda Pharmaceutical Co (4502.T) for an undisclosed amount last year.

Taro shares were up 2 percent at $51.75 in morning trade on the New York Stock Exchange. Sun Pharma shares closed down marginally at 746.10 rupees on Friday on the National Stock Exchange. (Reporting by Esha Dey in Bangalore and Kaustubh Kulkarni in Mumbai; Editing by Roshni Menon)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Market Eye

REUTERS SHOWCASE

Segway in India

Segway in India

Segway’s India business pegs hope on tech-savvy Modi  Full Article 

Cipla Shares

Cipla Shares

Cipla jumps after key generic launch.  Full Article 

Modi in Japan

Modi in Japan

Japan and India agree to boost strategic ties at summit.  Full Article 

Basel III Norms

Basel III Norms

RBI amends Basel III guidelines for banks.  Full Article 

Antitrust Probes

Antitrust Probes

U.S. business lobby says concerned China antitrust probes unfair.  Full Article 

Current Account

Current Account

Balance of payments surplus for third straight quarter.  Full Article 

Book Talk

Book Talk

Reema Abbasi and a glimpse of Pakistan’s Hindu past.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage